several patients with OLP, including those with severe cases that were refractory to a variety of approaches. Dosed orally, apremilast had an acceptable safety profile and good tolerability. Additional research will be necessary to fully understand its clinical efficacy and safety in OLP.
ACKNOWLEDGEMENTS
Dr. Bettencourt received editorial support in the preparation of this manuscript from Gary Cooper PhD, of p-value communications, funded by Celgene Corporation, Summit, NJ. The author directed, and is fully responsible for, all content and editorial decisions for this manuscript. The author meets the ICMJE criteria for authorship for this manuscript, takes responsibility for the integrity of the work as a whole, and has given final approval for the version to be published.
DISCLOSURES
The study was sponsored by Celgene Corporation, Summit, NJ. Dr. Bettencourt has no conflicts of interest to declare.
REFERENCES
- Davari P, Hsiao HH, Fazel N. Mucosal lichen planus: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):181-195.
- Gupta S, Jawanda MK. Oral lichen planus: an update on etiology, pathogenesis, clinical presentation, diagnosis and management. Indian J Dermatol. 2015;60(3):222-229.
- Werneck JT, Costa TO, Stibich CA, Leite CA, Dias EP, Silva JA. Oral lichen planus: study of 21 cases. An Bras Dermatol. 2015;90(3):321-326.
- Krupaa RJ, Sankari SL, Masthan KM, Rajesh E. Oral lichen planus: an overview. J Pharm Bioallied Sci. 2015;7(suppl 1):s158-s161.
- Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738-746.
AUTHOR CORRESPONDENCE
Miriam Bettencourt MD……............................................ drmiriam@cox.net
